Adaptive Biotechnologies cites NCCN MRD guidance update for clonoSEQ
Adaptive Biotechnologies says updated NCCN Guidelines for multiple myeloma now include a dedicated framework for routine MRD assessment and specifically reference clonoSEQ as an FDA-cleared MRD assay, with 10-6 sensitivity now preferred.